Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies

• Published in: Brain, behavior, and immunity behavior, and immunity, 2023-05, Vol.110, p.175-184
• Main Authors: De Bastiani, Marco Antônio, Bellaver, Bruna, Brum, Wagner S., Souza, Debora G., Ferreira, Pamela C.L., Rocha, Andreia S., Povala, Guilherme, Ferrari-Souza, João Pedro, Benedet, Andrea L., Ashton, Nicholas J., Karikari, Thomas K., Zetterberg, Henrik, Blennow, Kaj, Rosa-Neto, Pedro, Pascoal, Tharick A., Zimmer, Eduardo R.
• Format: Article
• Language: English
• Subjects: Alzheimer Disease; Alzheimer Disease - metabolism; Alzheimer’s disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Peptides - metabolism; Animals; Astrocytes; Astrocytes - metabolism; Biomarker; Biomarkers; Biomarkers - metabolism; GFAP; Glial Fibrillary Acidic Protein; Glial Fibrillary Acidic Protein - metabolism; Hippocampus; Hippocampus - metabolism; Humans; metabolism; Mice; Neurosciences; Neurovetenskaper; Tau; tau Proteins; tau Proteins - metabolism
• ISSN: 0889-1591; 1090-2139; 1090-2139
• DOI: 10.1016/j.bbi.2023.03.001

•GFAP-positive astrocytes driven by Aβ or tau pathologies present distinct molecular profiles and scarce differential gene overlap.•Amyloid and tau pathologies trigger distinct enrichment of functional categories in GFAP-positive astrocytes.•Gene Ontology terms in GFAP-positive astrocytes are differentially driven by Aβ and tau pathologies. In Alzheimer’s disease clinical research, glial fibrillary acidic protein (GFAP) released/leaked into the cerebrospinal fluid and blood is widely measured and perceived as a biomarker of reactive astrogliosis. However, it was demonstrated that GFAP levels differ in individuals presenting with amyloid-β (Aβ) or tau pathologies. The molecular underpinnings behind this specificity are little explored. Here we investigated biomarker and transcriptomic associations of hippocampal GFAP-positive astrocytes with Aβ and tau pathologies in humans and mouse models. We studied 90 individuals with plasma GFAP, Aβ- and Tau-PET to investigate the association between biomarkers. Then, transcriptomic analysis in hippocampal GFAP-positive astrocytes isolated from mouse models presenting Aβ (PS2APP) or tau (P301S) pathologies was conducted to explore differentially expressed genes (DEGs), Gene Ontology terms, and protein–protein interaction networks associated with each phenotype. In humans, we found that plasma GFAP associates with Aβ but not tau pathology. Unveiling the unique nature of hippocampal GFAP-positive astrocytic responses to Aβ or tau pathologies, mouse transcriptomics showed scarce overlap of DEGs between the Aβ. and tau mouse models. While Aβ GFAP-positive astrocytes were overrepresented with DEGs associated with proteostasis and exocytosis-related processes, tau hippocampal GFAP-positive astrocytes presented greater abnormalities in functions related to DNA/RNA processing and cytoskeleton dynamics. Our results offer insights into Aβ- and tau-driven specific signatures in hippocampal GFAP-positive astrocytes. Characterizing how different underlying pathologies distinctly influence astrocyte responses is critical for the biological interpretation of astrocyte biomarkers and suggests the need to develop context-specific astrocyte targets to study AD. This study was supported by Instituto Serrapilheira, Alzheimer’s Association, CAPES, CNPq and FAPERGS.